Known targets — ChEMBL curated mechanism
ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG
The experimentally established mechanism targets of Iodide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 2/20 | 0.43 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 6/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.43 |
| ▸ | HPGD | P15428 | 4/20 | 0.43 |
| ▸ | GLA | P06280 | 3/20 | 0.43 |
| ▸ | NQO2 | P16083 | 5/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.39 |
| ▸ | POLB | P06746 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MAOA | P21397 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | CASP1 | P29466 | 2/20 | 0.39 |
| ▸ | CASP7 | P55210 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | DRD1 | P21728 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL1146714 | 0.97 | MAPT (0.50) | MAPTALDH1A1HPGDGLAACHE | |
| SCHEMBL50667 | 0.97 | MAPT (0.56) | MAPTALDH1A1HPGDGLAACHE | |
| Iodide SCHEMBL1146708 | 0.95 | MAPT (0.48) | MAPTALDH1A1HPGDGLAACHE | |
| Hydrochloric Acid SCHEMBL740017 | 0.94 | MAPT (0.53) | MAPTALDH1A1HPGDGLAACHE | |
| Hydrochloric Acid SCHEMBL31542018 | 0.94 | MAPT (0.53) | MAPTALDH1A1HPGDGLAACHE | |
| SCHEMBL3360974 | 0.84 | MAPT (0.42) | MAPTALDH1A1HPGDGLAACHE | |
| SCHEMBL8987972 | 0.82 | MAPT (0.40) | MAPTALDH1A1HPGDGLAACHE | |
| Iodide SCHEMBL12813166 | 0.82 | HTR3A (0.47) | MAPTALDH1A1HPGDGLAACHE | |
| Iodide SCHEMBL12813168 | 0.80 | HTR3A (0.46) | MAPTALDH1A1HPGDGLAACHE | |
| SCHEMBL12273001 | 0.79 | HTR3A (0.48) | MAPTALDH1A1HPGDGLAACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4611744-A1 | METHODS OF REDUCING MIRO1 OR PHOSPHORYLATED ALPHA-SYNUCLEIN | Acurex Biosciences Corporation (US) | 2025-09-10 | — | — | EP | disclosed |
| WO-2024097632-A1 | METHODS OF REDUCING MIRO1 OR PHOSPHORYLATED ALPHA-SYNUCLEIN | ACUREX BIOSCIENCES CORPORATION (US) | 2024-05-10 | — | — | WO | disclosed |
| EP-2585073-B1 | ANTIVIRAL COMPOUNDS | PROSETTA ANTIVIRAL INC (US) | 2016-04-27 | — | — | EP | disclosed |
| US-8785434-B2 | Antiviral compounds | PROSETTA ANTIVIRAL INC. (US) | 2014-07-22 | — | — | US | disclosed |
| EP-2585073-A1 | ANTIVIRAL COMPOUNDS | Prostetta Antiviral Inc. (US) | 2013-05-01 | — | — | EP | disclosed |
| US-20120157435-A1 | Antiviral Compounds | PROSETTA ANTIVIRAL INC. (US) | 2012-06-21 | — | — | US | disclosed |
| US-8188074-B2 | Diamino-substituted phenothiazinium compound; antimicrobial photosensitisers effective against Gram negative bacteria, Gram positive bacteria; photodynamic therapy | PHOTOPHARMICA LIMITED (GB) | 2012-05-29 | — | — | US | disclosed |
| WO-2011137447-A1 | ANTIVIRAL COMPOUNDS | PROSTETTA ANTIVIRAL INC. (US) | 2011-11-03 | — | — | WO | disclosed |
| US-7915254-B2 | Photosensitizers for photodynamic therapy; killing tissue, cells; anticancer agents | PHOTOPHARMICA LIMITED (GB) | 2011-03-29 | — | — | US | disclosed |
| US-7855197-B2 | Biologically active methylene blue derivatives | PHOTOPHARMICA LIMITED (GB) | 2010-12-21 | — | — | US | disclosed |
| US-7732439-B2 | Biologically active methylene blue derivatives | PHOTOPHARMICA LIMITED (GB) | 2010-06-08 | — | — | US | disclosed |
| US-20080312219-A1 | Diamino-substituted phenothiazinium compound; antimicrobial photosensitisers effective against Gram negative bacteria, Gram positive bacteria; photodynamic therapy | PHOTOPHARMICA LIMITED (GB) | 2008-12-18 | — | — | US | disclosed |
| US-20080275033-A1 | BIOLOGICALLY ACTIVE METHYLENE BLUE DERIVATIVES | PHOTOPHARMICA LIMITED (GB) | 2008-11-06 | — | — | US | disclosed |
| US-20080268033-A1 | BIOLOGICALLY ACTIVE METHYLENE BLUE DERIVATIVES | PHOTOPHARMICA LIMITED (GB) | 2008-10-30 | — | — | US | disclosed |
| US-20080261960-A1 | Biologically active methylene blue derivatives | PHOTOPHARMICA LIMITED (GB) | 2008-10-23 | — | — | US | disclosed |
| US-7371744-B2 | Photosensitizers for photodynamic therapy; killing tissue, cells; anticancer agents | PHOTOPHARMICA LIMITED (GB) | 2008-05-13 | — | — | US | disclosed |
| EP-1687286-A1 | DEVELOPMENTS IN BIOLOGICALLY ACTIVE METHYLENE BLUE DERIVATIVES (2) | Photopharmica Limited (GB) | 2006-08-09 | — | — | EP | disclosed |
| WO-2005054217-A1 | DEVELOPMENTS IN BIOLOGICALLY ACTIVE METHYLENE BLUE DERIVATIVES (2) | PHOTOPHARMICA LIMITED (GB) | 2005-06-16 | — | — | WO | disclosed |
| US-20040147508-A1 | Biologically active methylene blue derivatives | PHOTOPHARMICA LIMITED | 2004-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261960-A1 | Biologically active methylene blue derivatives | XPA, XPOT, XPO7 | ACHE 4086/4885CHRM1 1669/4885MAPT 1629/4885 |
| US-20120157435-A1 | Antiviral Compounds | MAVS, ZC3HAV1, EIF2AK2 | ACHE 1024/4885CHRM1 4566/4885MAPT 693/4885 |
| US-20040147508-A1 | Biologically active methylene blue derivatives | HCCS, CYBA, HMBS | ACHE 4014/4885CHRM1 1062/4885MAPT 1623/4885 |
| US-20080268033-A1 | BIOLOGICALLY ACTIVE METHYLENE BLUE DERIVATIVES | XPA, XPOT, XPO4 | ACHE 4552/4885CHRM1 1364/4885MAPT 2428/4885 |
| US-20080312219-A1 | Diamino-substituted phenothiazinium compound; antimicrobial photosensitisers effective against Gram negative bacteria, Gram positive bacteria; photodynamic therapy | XPA, XPOT, XPO4 | ACHE 4679/4885CHRM1 3714/4885MAPT 1008/4885 |
| US-20080275033-A1 | BIOLOGICALLY ACTIVE METHYLENE BLUE DERIVATIVES | XPA, XPO7, XPO4 | ACHE 2403/4885CHRM1 948/4885MAPT 3845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.